Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Alkermes plc. Director's Dealing 2011

Sep 21, 2011

31048_dirs_2011-09-21_67601478-d807-4e73-8fef-95172cc8276e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: Alkermes plc. (ALKS)
CIK: 0001520262
Period of Report: 2011-09-16

Reporting Person: SKALETSKY MARK B (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2011-09-16 Common Stock D 5000 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2011-09-16 Non Qualified Stock Option (Right to Buy) $14.49 D 24000 Disposed 2014-06-01 Common Stock (24000) Direct
2011-09-16 Non Qualified Stock Option (Right to Buy) $11.84 D 15000 Disposed 2014-09-23 Common Stock (15000) Direct
2011-09-16 Non Qualified Stock Option (Right to Buy) $16.77 D 20000 Disposed 2015-09-23 Common Stock (20000) Direct
2011-09-16 Non Qualified Stock Option (Right to Buy) $14.04 D 20000 Disposed 2016-09-21 Common Stock (20000) Direct
2011-09-16 Non Qualified Stock Option (Right to Buy) $18.29 D 20000 Disposed 2017-10-09 Common Stock (20000) Direct
2011-09-16 Non Qualified Stock Option (Right to Buy) $11.44 D 20000 Disposed 2018-10-07 Common Stock (20000) Direct
2011-09-16 Non Qualified Stock Option (Right to Buy) $8.98 D 20000 Disposed 2019-10-06 Common Stock (20000) Direct
2011-09-16 Non Qualified Stock Option (Right to Buy) $14.92 D 20000 Disposed 2020-10-05 Common Stock (20000) Direct

Footnotes

F1: Received in exchange for shares of Alkermes, Inc. common stock in connection with the merger of Alkermes, Inc. and the global drug delivery technologies business of Elan (the "Merger"). On 9/16/11, the effective date of the Merger, the closing price of ALKS was $16.57 per share.

F2: These options are fully vested in accordance with their terms.

F3: Form 4 Amendment being filed to correctly reflect that no price was paid by the reporting person for receipt of these derivative securities by eliminating the price in column 8.

F4: Received in exchange for, and having substantially the same terms as, stock options of Alkermes, Inc. common stock in connection with the Merger.